Publications by authors named "Anthony Angyal"
Curr Gastroenterol Rep
March 2024
Article Synopsis
- The review discusses the purpose of biosimilars in reducing high costs associated with biologic treatments for inflammatory bowel disease (IBD) and highlights their current underutilization.
- Biosimilars, such as infliximab, adalimumab, and ustekinumab versions, have been shown to be similarly effective and safe as their branded counterparts, but their adoption is hindered by concerns over efficacy, safety, and market delays.
- To improve the uptake of biosimilars, collaboration among clinicians, patients, and healthcare systems is essential to enhance access and capitalize on cost-saving benefits.
